866-997-4948(US-Canada Toll Free)

Brivanib Analysis and Market Forecasts from 2013 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 29 Pages


GlobalDatas pharmaceuticals report, Brivanib Analysis and Market Forecasts from 2013 to 2020 provides Brivanib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Brivanib including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Brivanib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Brivanib in the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Liver Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 5
2.3.1 Hepatitis B Infection 5
2.3.2 Hepatitis C Infection 5
2.3.3 Alcohol 5
2.3.4 Aflatoxin B1 6
2.3.5 Hemochromatosis 6
2.3.6 Diabetes and Obesity 6
2.3.7 Cirrhosis 6
2.4 GlobalData Report Guidance 6

3 Liver Cancer : Market Characterization 7
3.1 Liver Cancer Market 7
3.2 Liver Cancer Market Forecasts and CAGR 7
3.3 Drivers for the Liver Cancer Market 7
3.3.1 High Incidence 8
3.3.2 High Mortality 8
3.3.3 Large Unmet Need 9

4 TumorNodeMetastases (TNM) Classification of Liver Cancer 10

5 Brivanib 11
5.1 Introduction 11
5.2 Mechanism of Action 11
5.3 Clinical Studies 11
5.4 Indications of Brivanib 12
5.5 Factors Affecting Sales of Brivanib 12
5.5.1 Oral Administration 12
5.5.2 Second Line Treatment 12
5.5.3 Adjuvant to TACE (Transcatheter Arterial Chemoembolization) 13
5.5.4 Dual Selective Inhibition 13
5.6 Drug Risk Benefit Score 13
5.6.1 Efficacy 13
5.6.2 Safety 13
5.6.3 Compliance 14
5.6.4 Dosing Convenience 14
5.7 Intensity of Competition 14
5.8 Sales forecast 14
5.8.1 Target patient Pool of Brivanib 14
5.8.2 Dosing 15
5.8.3 Market Penetration 15
5.8.4 Annual Cost of Therapy 15
5.8.5 Sales Projections of Brivanib 16

6 Liver Cancer Market: Appendix 25
6.1 Market Definitions 25
6.2 List of Abberiviations 25
6.3 Research Methodology 25
6.3.1 Coverage 25
6.3.2 Secondary Research 25
6.3.3 Forecasting 26
6.3.4 Number of Patients Approved to take the Drug 26
6.3.5 Net Penetration of Drug 27
6.3.6 Net Annual Dosing 27
6.3.7 Annual Cost of Therapy 27
6.3.8 Primary Research 27
6.3.9 Expert Panels 28
6.4 Drug Sales Estimates Model 28
6.5 Contact Us 28
6.6 Disclaimer 28
6.7 Sources 29

List of Table


Table 1: Liver Cancer, Incidences and Mortality, 20082030 4
Table 2: Drug Risk Benefit Score of Brivanib 13
Table 3: Brivanib, Liver Cancer, The US, EU5 and Japan Sales Forecasts ($m), 20132020 16
Table 4: Brivanib, Liver Cancer, The US, Sales Forecasts ($m), 20132020 17
Table 5: Brivanib, Liver Cancer, The UK, Sales Forecasts ($m), 20132020 18
Table 6: Brivanib, Liver Cancer, France, Sales Forecasts ($m), 20132020 19
Table 7: Brivanib, Liver Cancer, Germany, Sales Forecasts ($m), 20132020 20
Table 8: Brivanib, Liver Cancer, Italy, Sales Forecasts ($m), 20132020 21
Table 9: Brivanib, Liver Cancer, Spain, Sales Forecasts ($m), 20132020 22
Table 10: Brivanib, Liver Cancer, Japan, Sales Forecasts ($m), 20132020 23

List of Chart


Figure 1: Fatality = [(% Distribution of Incidence) (% Distribution Mortality )] of Most Common Cancers 5
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 20102020 7
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 20082030 8
Figure 4: Oncology, Worldwide, Incidence (in millions), 20082030 8
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 20082030 9
Figure 6: Classification of Liver Cancer 10
Figure 7: Clinical Trials Results, Brivanib 12
Figure 8: Drug Model Diagram of Brivanib 15
Figure 9: Brivanib, Liver Cancer, The US, EU5 and Japan, Sales Forecasts ($m), 20132020 16
Figure 10: Brivanib, Liver Cancer, The US, Sales Forecasts ($m), 20132020 17
Figure 11: Brivanib, Liver Cancer, The UK Sales Forecasts ($m), 20132020 18
Figure 12: Brivanib, Liver Cancer, France, Sales Forecasts ($m), 20132020 19
Figure 13: Brivanib, Liver Cancer, Germany, Sales Forecasts ($m), 20132020 20
Figure 14: Brivanib, Liver Cancer, Italy, Sales Forecasts ($m), 20132020 21
Figure 15: Brivanib, Liver Cancer, Spain, Sales Forecasts ($m), 20132020 22
Figure 16: Brivanib, Liver Cancer, Japan, Sales Forecasts ($m), 20132020 23
Figure 17: Distribution of Brivanib Sales in Major Countries, 2020 24
Figure 18: Drug Model Diagram 26
Figure 19: Patients Approved for the Drug 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *